Richard Daniels

Chief Operating Officer at Primmune Therapeutics

Richard Daniels brings more than 25 years of experience in the pharmaceutical and biotech industry covering all stages of product development and commercialization in multiple therapeutic areas. Prior to joining Primmune Therapeutics, Mr. Daniels was Senior Vice President of Clinical Operations and R&D Planning at Intercept Pharmaceuticals where he was responsible for managing a ~$180M annual R&D budget across multiple development and in-market programs supporting the company’s liver-disease focus. Prior to Intercept Pharmaceuticals, Mr. Daniels spent 15 years at Amgen in increasing roles of responsibility, including the last 5 years as Executive Director and Oncology Therapeutic Area Lead where he was responsible for managing development and life-cycle activities for a portfolio of 20+ pipeline and marketed assets. Earlier in Mr. Daniels’ career, he held various scientific positions at Genicon Sciences (acquired by Life Technologies) and Agouron Pharmaceuticals (acquired by Pfizer). Mr. Daniels earned a B.S. in microbiology from the University of California, San Diego.

Timeline

  • Chief Operating Officer

    Current role

View in org chart